Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therapy and prognosis in pancreatic cancer.
Ming CuiSami ShoucairQuan LiaoXiaoyan QiuBenedict Kinny-KösterJoseph R HabibElie M GhabiJunke WangEun Ji ShinSean X LengSyed Z AliElizabeth D ThompsonJacquelyn W ZimmermanChristopher R ShubertKelly J LafaroRichard A BurkhartWilliam R BurnsLei ZhengJin HeYupei ZhaoChristopher L WolfgangXin YuPublished in: International journal of surgery (London, England) (2023)
Assessment of SIA-IgG on FNA specimens prior to NAT may help predict PR for PDAC. Additionally, SIA-IgG expression in treatment-naïve FNA specimens and surgically resected primary tumor specimens were predictive of the prognosis for PDAC.